# CasBio

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/casbio

- Industry: Biotechnology
- Headquarters: Shanghai, China
- Latest round: Seed (Apr 16, 2024)
- Investors on record: 1

## About

Based in Shanghai, China and founded in 2023, Shanghai Zhuanma Biotechnology Co., Ltd., dba CasBio, is a biotechnology company that focuses on the development of gene editing therapies. The founder and CEO, Yanming Guan has worked at Calimmune and Rampart Bioscience. In March 2026, CasBio closed Pre-A funding from MED-FINE Capital, Efung Capital, Lake Ventures.

The company is committed to the research and development of gene editing technology. It owns alphaCas®, an ultra-compact gene editor, a macro-genome-based gene editor mining platform, and can engineer ultra-compact gene editors as well as target screening and pipeline development. The gene editor is suitable for nonviral vectors and virus delivery platforms, and its developed pipeline has covered liver-targeted and non-liver-targeted directions.

The company generates revenue by providing gene editors.

## Funding rounds

- Seed, Apr 16, 2024 — MED-FINE Capital

## Investors

- MED-FINE Capital (https://capitalatlas.ai/funds/med-fine-capital) — Seed